Price$15.88+13.78 (+655.95%)
2025-06-032025-07-02
Latest news
25 items- SECSEC Form PRE 14A filed by Eyenovia Inc.PRE 14A - HYPERION DEFI, INC. (0001682639) (Filer)
- INSIDERChief Investment Officer Jung Hyunsu was granted 500,000 shares (SEC Form 4)4 - HYPERION DEFI, INC. (0001682639) (Issuer)
- INSIDERDirector Jacobson Rachel was granted 5,000 shares, increasing direct ownership by 384% to 6,301 units (SEC Form 4)4 - HYPERION DEFI, INC. (0001682639) (Issuer)
- INSIDERChief Executive Officer Rowe Michael M was granted 6,600 shares, increasing direct ownership by 480% to 7,975 units (SEC Form 4)4 - HYPERION DEFI, INC. (0001682639) (Issuer)
- INSIDERDirector Geltzeiler Michael S was granted 7,000 shares, increasing direct ownership by 690% to 8,015 units (SEC Form 4)4 - HYPERION DEFI, INC. (0001682639) (Issuer)
- INSIDERDirector Strahlman Ellen R was granted 5,000 shares, increasing direct ownership by 293% to 6,706 units (SEC Form 4)4 - HYPERION DEFI, INC. (0001682639) (Issuer)
- INSIDERSEC Form 3 filed by new insider Jung Hyunsu3 - HYPERION DEFI, INC. (0001682639) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Eyenovia Inc.SCHEDULE 13D/A - HYPERION DEFI, INC. (0001682639) (Subject)
- SECEyenovia Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - HYPERION DEFI, INC. (0001682639) (Filer)
- PREyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.Name change reflects company's leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol "HYPD" effective July 3rd Also announces official launch of the Kinetiq x Hyperion validator LAGUNA HILLS, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it is rebranding and changing its corporate name to Hyperion DeFi, Inc. Concurrent with the name change, the Company's
- PREyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain EngagementLAGUNA HILLS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it has acquired an additional 265,872 HYPE tokens, expanding its total holdings to 1,306,452 HYPE purchased at an average price of $34.83 per token. "We continue to see strong signals from the market and prospective partners affirming the importance of HYPE's role in next-generation financial infrastructure," said Hyunsu Jung, Chief Investment Officer of Eyenovia. "This latest token acq
- SECSEC Form 424B5 filed by Eyenovia Inc.424B5 - EYENOVIA, INC. (0001682639) (Filer)
- SECEyenovia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - EYENOVIA, INC. (0001682639) (Filer)
- PREyenovia Announces Co-Branded Validator with KinetiqLAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced a co-branded Hyperliquid validator with Kinetiq, a leading liquid staking protocol built natively for the Hyperliquid ecosystem. The validator marks a significant step in Eyenovia's onchain engagement strategy, utilizing its recent acquisition of 1,040,584.5 HYPE to contribute directly to network stability and security. Validator operations are further supported by infrastructure provided by Pier
- SECEyenovia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - EYENOVIA, INC. (0001682639) (Filer)
- PREyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development ProgramThe significant HYPE token position, acquired at an average price of approximately $34 per token, makes Eyenovia the first Nasdaq listed company to run a validator on Hyperliquid FDA registration of the Optejet User Filled Device (UFD) on track for September 2025; meaningful partnering discussions ongoing LAGUNA HILLS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced the closing of its previously announced $50 million private placement (PIPE) with ac
- PRChardan Expands into Digital Assets by Advising Strategic Crypto-Backed FinancingsNEW YORK, June 18, 2025 /PRNewswire/ -- Chardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and structuring a series of transactions that bridge traditional capital markets with the rapidly evolving world of blockchain and cryptocurrency. As part of its strategic push into crypto finance, Chardan has recently served as a strategic advisor and placement agent in the following notable transactions: Eyenovia's $50 Million PIPE to Acquire HYPE Tokens Chardan acted as sole placement agent in Eyenovi
- PREyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital GroupLAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced several key developments in support of its digital asset capital strategy. Avenue Capital Group, now the Company's largest common stockholder, has agreed to amend Eyenovia's senior secured debt to further support the Company as it builds its HYPE treasury and reserve of the HYPE token. Pursuant to the terms of the amendment, the maturity date of the debt has been extended from November 1, 2025 to
- PREyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve StrategyAnnounces private placement EYEN to become first U.S.-based publicly listed company to hold HYPE in its treasury Hyunsu Jung appointed Chief Investment Officer and Board Member LAGUNA HILLS, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company") today announced that it has entered into a securities purchase agreement (the "SPA") for a $50 million private placement in public equity (the "PIPE Financing") with institutional accredited investors. The Company will use the funds to build a reserve of a token called HYPE, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. The Company expects to receive
- SECEyenovia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - EYENOVIA, INC. (0001682639) (Filer)
- INSIDERSEC Form 4 filed by Large owner Avenue Capital Management Ii, L.P.4 - EYENOVIA, INC. (0001682639) (Issuer)
- INSIDERNew insider Avenue Capital Management Ii, L.P. claimed ownership of 30,619 shares (SEC Form 3)3 - EYENOVIA, INC. (0001682639) (Issuer)
- SECSEC Form 424B5 filed by Eyenovia Inc.424B5 - EYENOVIA, INC. (0001682639) (Filer)
- SECEyenovia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - EYENOVIA, INC. (0001682639) (Filer)
- PREyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial ResultsEyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the user-filled Optejet, and remains on track to file for U.S. device regulatory approval in September 2025 Reduced ongoing cash burn by approximately 70% versus prior year and improved debt repayment terms LAGUNA HILLS, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing the proprietary Optejet® topical ophthalmic medication dispensing platform, today provided updates on its potential merger with Betaliq and the ongoing devel
EYEN FAQ
7 questionsWhat does Eyenovia Inc. do?
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print (MAP) platform technology. The company focuses on to develop clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. Its pipelines focus on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with...Where does EYEN stock trade?
Eyenovia Inc. (EYEN) is listed on NASDAQ.What sector and industry is EYEN in?
Eyenovia Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Eyenovia Inc. go public?
Eyenovia Inc. (EYEN) completed its IPO in 2018.What are analysts saying about EYEN?
Eyenovia Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Neutral with a $200.00 price target on 2024-11-18. Recent price targets cluster around $200.00.What companies are similar to EYEN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare EYEN side-by-side with any of them on Quantisnow.How can I track EYEN on Quantisnow?
Quantisnow aggregates Eyenovia Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EYEN to receive live email and push alerts on every new disclosure.